CHICAGO — Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus trastuzumab and pertuzumab across patients with HER2-positive ...

Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy ...

Novel combinations include pertuzumab (a HER2 dimerization inhibitor), lapatinib (a HER1/HER2 tyrosine kinase inhibitor), bevacizumab (an antiangiogenic agent), ... Understanding the Mechanisms Behind ...

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line ...

In the landmark CLEOPATRA study (NCT00567190), THP significantly improved median overall survival (OS) from 40.8 months (95% CI, 35.8-48.3) with placebo, trastuzumab, and docetaxel to 56.5 months ...

Topline results were announced from a phase 3 trial evaluating fam-trastuzumab deruxtecan-nxki in combination with pertuzumab as a first-line treatment for patients with human epidermal growth ...

The phase 3 trial compares trastuzumab deruxtecan (Enhertu; AstraZeneca, Daiichi Sankyo) in combination with pertuzumab (Perjeta, Genentech) vs. current first-line standard of care in patients ...

CHICAGO -- First-line trastuzumab deruxtecan (T-DXd) combined with pertuzumab (Perjeta) improved progression-free survival (PFS) in HER2-positive locally advanced or metastatic breast cancer ...

Novel combinations include pertuzumab (a HER2 dimerization inhibitor), lapatinib (a HER1/HER2 tyrosine kinase inhibitor), bevacizumab (an antiangiogenic agent), ... Understanding the Mechanisms Behind ...

Median duration of follow-up was nearly 2.5 years (29.2 months). As of the data cut-off, 302 (39.6%) patients remained on treatment, 174 in the ENHERTU plus pertuzumab arm and 128 in the THP arm.

Positive high-level results from a planned interim analysis of the DESTINY-Breast09 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab demonstrated ...